Accepted for Publication: July 7, 2014.
Published Online: November 3, 2014. doi:10.1001/jamaneurol.2014.2376.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: Gelfand, Genrich, Tihan, Cree.
Drafting of the manuscript: Gelfand.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Gelfand, Cree.
Administrative, technical, or material support: Genrich, Green.
Study supervision: Green, Tihan, Cree.
Conflict of Interest Disclosures: Dr Gelfand reported receiving compensation for medical legal consulting related to central nervous system inflammatory disease. Dr Green reported providing consulting services for Prana Pharmaceuticals, Novartis, Biogen, Roche, and Acorda Pharmaceuticals. He also reported serving on an end point adjudication committee for a Biogen-sponsored trial and providing expert legal advice for Mylan Pharmaceuticals. Dr Cree reported receiving personal compensation for consulting from Abbvie, Biogen Idec, EMD Serono, Genzyme/sanofi-aventis, MedImmune, Novartis, and Teva Neurosciences and contracted research support (including clinical trials) from Acorda, Avanir, Biogen Idec, EMD Serono, Hoffman La Roche, and Novartis. No other disclosures were reported.
Funding/Support: This study was supported by an American Academy of Neurology Clinical Research Training Fellowship (Dr Gelfand) and National Institutes of Health National Center for Advancing Translational Sciences grant KL2TR000143 (Dr Gelfand).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Sam Arnow, BA (University of California, San Francisco), assisted with data analysis and figure generation. He did not receive compensation.